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monthly (p = 0.001). In contrast, AVJ ablations increased. During the same time periods,
an average of 6 AVJ ablations were performed each month prior versus a average of 10
after the trial data were presented (p = 0.001).
We conclude that AFFIRM and RACE trial data resulted in an early change in the man-
agement of patients with AF at these 2 institutions with a shift in practice towards a rate
control strategy.
9:00 a.m.
875-3 Suppression of Paroxysmal Atrial Tachyarrhythmias: 
Results of the SOPAT Trial
Monica Patten, Renke Maas, Bernd Lüderitz, Frank Sonntag, R. Hatala, M. Dluzniewski, 
G. Opolski, Thomas Meinertz, University Hospital Hamburg, Eppendorf, Hamburg, 
Germany
SOPAT is a prospective, double-blind, randomized trial to answer the following questions:
1. What is the average rate of spontaneous events of symptomatic atrial fibrillation
(sAF)? 2. Does treatment with sotalol or quinidine + verapamil significantly reduce the
recurrence rate of sAF? 3. How safe are these drugs?
Over 60 months 1033 pts. (mean age 60 yrs, 63% male, 12% heart failure) presenting at
least one episode of sAF one month prior to enrolement were recruted in 171 centres in
Germany, Poland and the Slovak Republic. Pts. were randomized to either 160 mg
sotalol bid (262 pts.), 160 mg quinidine + 80 mg verapamil (Q+V) bid (263 pts.), Q+V tid
(256 pts.) or placebo (252 pts.). Pts. received an ECG recorder (RhythmCard®, Instro-
medix) to record one 1-min ECG daily and in case of symptoms. ECGs were transmitted
by telephone to a central analysis unit together with pts. symptoms. The primary endpoint
was defined as the time to first recurrence of sAF or study discontinuation. Secondary
endpoint was the number of days with AF. During the one year follow-up 296260 Tele-
ECGs were transmitted and analysed.
The mean follow-up period was 233 ± 152 d. Premature study termination was highest in
the placebo group with 59% vs. 41% under Q+V tid, and 42% under Q+V bid and sotalol.
Regarding the primary endpoint all active treatments were superior to placebo and equiv-
alent to each other. A total of 756 pts. reached the primary endpoint within 106 ± 9 d
(mean ± SEM) under placebo, vs. Q+V tid: 150 ± 10 d (p= 0.0061), vs. Q+V bid: 149 ± 11
d (p= 0.0006), vs. Sotalol: 146 ± 9 d (p= 0.0007). Burden of sAF, determined as the rela-
tive number of days with sAF, was significantly reduced in all treatment groups compared
to placebo (mean ± SD: 6.1 ± 13.5)vs. Q+V tid (3.4 ± 12, p=0.0001), Q+V bid (4.5 ± 12.3,
p=0.008), and Sotalol (2.9 ± 6.5, p=0.026). A total of 6 deaths, 18 syncopes, and 1 ven-
tricular tachycardia occurred with a comparable risk profile for all treatment groups.
In conclusion, treatment with Q+V is equivalent to sotalol in reducing the recurrence rate
of symptomatic AF with a low risk of life-threatening events in pts. with lone AF or minimal
structural heart disease.
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875-4 The Incidence of Cerebral Embolism After 
Percutaneous Occlusion of the Left Atrial Appendage: A 
Serial and Prospective Study Using Cerebral Magnetic 
Resonance Imaging Scanning
Heyder Omran, Harald Schmidt, Peter Bernhardt, Christoph Hammerstingl, Stephanie 
Kuntz-Hehner, Thorsten Sommer, Berndt Lüderitz, David Hardung, University of Bonn, 
Bonn, Germany
Background: Percutaneous left atrial appendage (LAA) occlusion has been introduced as
an alternative treatment in patients with atrial fibrillation and increased thromboembolic
risk. However, the long term risk of cerebral embolism under this new treatment is
unknown. The aim of the study was to evaluate the long-term risk of cerebral embolism
by serial cerebral MRI scanning.
Methods: 20 Patients with contraindications to warfarin or bleeding complications under
oral anticoagulation were enrolled in the study. Serial neurological and echocardio-
graphic examinations were undertaken prior to and during the procedure and in addition
at 1 month, 2 months, 6 and 12 months. Cerebral MRI including diffusion weighted
sequences was performed prior to the procedure, 48 hours after and 6 and 12 months
after the procedure to assess for cerebral microembolism.
Results: Cerebral MRI performed prior to the occlusion procedure detected the presence
of former cerebral embolism in 8 out of the 20 patients. Follow-up MRI studies excluded
the presence of new cerebral microembolism in all patients. TTE and TEE examinations
did not reveal de novo thrombus formation in the LA or thrombotic appositions on the sur-
face of the occlusion device.
Conclusions: Long term follow-up of patients with occlusion of the left atrial appendage
did not reveal cerebral thromboembolism on serial cerebral MRI. Percutaneous left atrial
appendage occlusion is an alternative treatment in patients at high risk of thromboembo-
lism and contraindications to oral anticoagulation therapy.
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875-5 Randomized Trial of Two Antiarrhythmic Agents 
(Amiodarone and Sotalol) in Patients With Atrial 
Fibrillation for Whom Direct Current Cardioversion Is 
Planned
Kunadian Vijayalakshmi, Michael J. Stewart, James A. Hall, Adrian Davies, Mark A. de 
Belder, The James Cook University Hospital, Middlesbrough, United Kingdom
Anti-arrhythmic agents enhance maintenance of sinus rhythm (SR) following direct cur-
rent cardioversion (DCC) for atrial fibrillation (AF) but there are few comparative trials.
Aims: (1)To establish whether taking amiodarone or sotalol (at standard clinical doses) is
better at achieving chemical cardioversion within the 6 weeks prior to planned DCC. (2)To
establish whether DCC is more likely to be successful on an anti-arrhythmic agent and
(3) to establish whether patients successfully cardioverted to SR are more likely to stay in
SR over 6 months if taking a drug and if so to establish whether one agent is better than
the other.
Methods: Randomised, prospective, non-blinded, controlled study of treatment with
either amiodarone, sotalol or no anti-arrhythmic agent to start 6 weeks prior to DCC, and
treatment to continue for a further 6 months. Patients with time of onset of AF within the
last 1 year were included. 94 patients were enrolled in the study (nil group n=31, sotalol
n=36 and amiodarone n=27). Follow up visits were at 6 weeks and 6 months post DCC.
Results: A total of 7 (25%) patients in the amiodarone group (A), 7 (19%) patients in the
sotalol group (S) were chemically cardioverted to SR, compared to none (0%) in the no
anti-arrhythmic group (N) [p=0.002 (AvN), 0.01 (SvN), 0.5 (AvS) respectively]. A total of
26/29 (90%) patients in the sotalol group were successfully cardioverted to SR compared
to 15/20 (75%) patients in the amiodarone group and 23/31 (74%) patients in the no anti-
arrhythmic group [p=0.03 (SvA), 0.05 (SvN), 0.9 (AvN) respectively]. At 6 month review
17 (62%) patients in the amiodarone group were in SR compared to 14 (38%) patients in
sotalol group and only 5 (16%) patients in the no anti-arrhythmic group [p=0.05 (AvS),
<0.05 (AvN) respectively]. Intention to treat and actually treated analysis gave similar
results.
Conclusion: Treatment with either amiodarone or sotalol for 6 weeks had equal efficacy
in achieving chemical cardioversion before planned DCC. Sotalol significantly increased
the chance of DCC producing SR. After successful cardioversion, amiodarone signifi-
cantly reduced the rate of reversion to AF and increased the chance of being in SR at 6
months
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875-6 Early Recurrence of Arrhythmia Is Common in Patients 
Taking Amiodarone or Type IC Agents for Treatment of 
Atrial Fibrillation or Atrial Flutter
Thomas H. Hauser, Duane S. Pinto, Mark E. Josephson, Peter Zimetbaum, Beth Israel 
Deaconess Medical Center, Boston, MA, Harvard Medical School, Boston, MA
Background: Amiodarone use for the prevention of recurrent atrial fibrillation or flutter
requires drug loading over several weeks. The rate of recurrent arrhythmia during amio-
darone loading has not been investigated. We compared the rates of recurrent arrhyth-
mia in patients treated with amiodarone and type IC agents, which do not require drug
loading.
Methods: We prospectively monitored a cohort of patients with ambulatory loop record-
ers during outpatient drug loading after spontaneous or electrical cardioversion to sinus
rhythm.
Results: The study cohort comprised 339 patients who were treated with amiodarone
(212), propafenone (64) or flecainide (63). Patients taking amiodarone were older (74 ±
11 vs. 59 ± 12, p <0.001) and more likely to have left ventricular dysfunction (80 [39%] vs.
8 [7%], p <0.001). Arrhythmia recurred in 106 (31.3%) and was persistent in 44 (13.0%).
The incidence of recurrent arrhythmia at 15 days was much less in patients treated with
amiodarone compared to those treated with a type IC agent (25.4% vs. 42.5%, p <
0.001) (Figure). Persistent arrhythmia was also much less in patients treated with amio-
darone (9.9% vs. 19.2% at 15 days, p = 0.011). Of those with recurrent arrhythmia, 58
(55%) were asymptomatic.
Conclusion: Recurrent arrhythmia is common and frequently asymptomatic during drug
loading with both amiodarone and type IC agents but is usually not persistent. The inci-
dence of recurrent arrhythmia during drug loading is much less with amiodarone com-
pared to type IC agents. 
